ArticleHealth services research2026
Health Insurance Type and Lung Cancer Stage Shift Following Coverage of Screening.
Article in Health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo examine the role of insurance coverage of lung cancer screening in driving shifts in lung cancer stage at diagnosis. STUDY SETTING AND
designWe performed difference-in-differences (DID) analyses to compare changes in the proportion of early-stage lung cancer diagnosis between pre-coverage (2007-2014) and post-coverage (2015-2019) periods across insurance groups. DATA SOURCES AND ANALYTIC SAMPLE: Using the National Cancer Institute's Surveillance, Epidemiology, and End Results database, we identified patients with non-small cell lung cancer aged 55-77 years and diagnosed between 2007 and 2019. Health insurance at diagnosis was categorized as private, Medicare (fee-for-service [FFS], FFS with supplemental private coverage, FFS with Medicaid, and Medicare Advantage with and without Medicaid), Medicaid (FFS and managed care), military health plans, and uninsured. PRINCIPAL
findingsAmong 227,112 patients, 63,676 (28.04%) had private insurance, 130,770 (57.58%) Medicare, 14,982 (6.60%) Medicaid, 5941 (2.62%) military health insurance, and 11,743 (5.17%) were uninsured. Compared with uninsured patients, a significantly greater increase in the proportion of early-stage lung cancer diagnosis between pre-coverage and post-coverage periods was observed among Medicaid patients (DID = 2.88 percentage points [ppt], 95% CI 0.73-5.02 ppt), but not patients with private insurance, Medicare, or military health insurance. Among Medicaid beneficiaries, those in managed care showed a significantly greater shift compared with those in FFS during 4-5 years post-coverage (DID = 8.22 ppt, 95% CI 4.51-11.93 ppt). Among Medicare FFS beneficiaries, dual enrollment in Medicaid was associated with a significantly smaller increase in the proportion of early-stage diagnosis compared with FFS-only enrollment during 4-5 years post-coverage (DID = -4.40 ppt, 95% CI [-6.40]-[-2.40] ppt).
conclusionsThe results suggest that beneficial stage shifts following the recommendation for lung cancer screening varied by health insurance status and type. Addressing patient, provider, and system-level barriers to lung cancer screening and downstream care is essential to translate lung cancer screening coverage into earlier-stage diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.